Nordic Bioscience
Nordic Bioscience is a Danish biomarker company that develops proprietary extracellular matrix (ECM) neo-epitope assays and laboratory services for pharmaceutical, biotechnology, and academic clients worldwide to support drug development, clinical trial enrichment, and chronic disease diagnostics.
- Company typePrivate
- Founded1989
- HeadquartersHerlev, Denmark
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Nordic Bioscience does
Nordic Bioscience is a Danish biomarker company founded in 1989 and headquartered in Herlev, Denmark, specializing in preclinical and clinical drug development support through proprietary extracellular matrix (ECM) biomarkers. The company operates the Nordic ProteinFingerPrint Technology platform, which uses neo-epitope-specific monoclonal antibodies to quantify small collagen fragments released during tissue remodeling, enabling non-invasive assessment of fibrosis, inflammation, and fibro-inflammatory signaling across cardiovascular, hepatic, renal, gastrointestinal, rheumatic, oncology, respiratory, neuroscience, and metabolic diseases. Its portfolio spans 150+ biomarkers (60+ proprietary Nordic assays) including flagship products nordicPRO-C3, nordicPRO-C6/Endotrophin, CPa9-HNE, and RheumaTrace, validated through 700+ peer-reviewed publications and used for patient stratification, pharmacodynamic monitoring, and treatment response assessment in clinical trials.
The company serves over 100 major pharmaceutical and biotechnology companies (including Eli Lilly, Bristol Myers Squibb, Roche Diagnostics, Madrigal Pharmaceuticals, and Pliant Therapeutics) plus academic research institutions through three integrated business segments. R&D Services delivers biomarker analysis from the company's CAP/CLIA-certified central laboratory in Herlev, generating DKK 527M in FY2024 revenue with 39% YoY growth. Clinical Diagnostics is monetized through an OEM/embedded licensing model via Roche Diagnostics' cobas e platform (PRO-C3 launched commercially in May 2025 following FDA approval) and a Kit in a Box manual ELISA product line for research use only. Drug Development is operated through wholly-owned subsidiary KeyBioscience, which holds an extended strategic collaboration with Eli Lilly for DACRA molecules in obesity and metabolic diseases. The company is privately held under KKR private equity ownership (invested March 2021) with Morten Karsdal as CEO.
Nordic Bioscience firmographics
Firmographics- Name
- Nordic Bioscience
- Legal name
- Nordic Bioscience A/S
- Website
- https://nordicbioscience.com
- Company type
- Private
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Nordic Bioscience is a Danish biomarker company that develops proprietary extracellular matrix (ECM) neo-epitope assays and laboratory services for pharmaceutical, biotechnology, and academic clients worldwide to support drug development, clinical trial enrichment, and chronic disease diagnostics.
- Ownership category
- akta.pro rank
Nordic Bioscience industry classification
Industry- Product category
- Biomarker Assay Development & Clinical Laboratory Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)
- akta.pro secondary industries
- Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Translational Medicine & Biomarkers (HLAIALAF), Proteomics & Biomarker Analytical Testing (HLAGADAG), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where Nordic Bioscience is headquartered
LocationHeadquarters
- HQ city
- Herlev
- HQ country
- Denmark
- HQ region
- Europe
Offices2 records
Markets served
Nordic Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- R&D Services: Laboratory services for biotech and pharmaceutical industries including biomarker analysis, preclinical and clinical sample analysis, and drug development support. Revenue increased 39% year-over-year, serving over 100 major pharmaceutical and biotechnology companies
- Clinical Diagnostics: Partnership with Roche leveraging validated ECM biomarkers for diagnostic purposes. Biomarkers measured on Roche Cobas platform for IVD-based decision making
- Drug Development: Development of DACRA molecules with Eli Lilly as potential new class of treatment for obesity and other indications. KeyBioscience subsidiary manages this collaboration
- Biomarker Kits and Products: Kit in a Box products - convenient lab-ready biomarker products for research use only. Includes Nordic assays portfolio of 60+ biomarkers sold directly to research institutions and pharma companies
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Nordic Bioscience product offering
Product offeringCore offering
Nordic Bioscience develops and commercializes proprietary neo-epitope biomarker assays targeting extracellular matrix (ECM) protein fragments for pharmaceutical and biotechnology drug development. Its core offerings are delivered through two channels: (1) CAP/CLIA-accredited central laboratory biomarker analysis services and (2) Kit in a Box manual ELISA products for Research Use Only. The company also licenses biomarkers to Roche Diagnostics for global IVD distribution on the Cobas platform and develops DACRA drug candidates through its KeyBioscience subsidiary.
Product overview
Nordic Bioscience is a Danish biomarker company offering a unified product ecosystem centered on its proprietary Nordic ProteinFingerPrint Technology platform. The core offering consists of biomarker assays (nordicPRO-C3, nordicPRO-C6, RheumaTrace, CPa9-HNE, Endotrophin) and the FIB-NIT Panel for fibrosis assessment, available via two delivery models: CAP/CLIA-accredited Laboratory Services or Kit in a Box (manual ELISA kits for RUO). The portfolio spans 77+ Nordic proprietary assays and 100+ commercial assays across 10 therapeutic areas. The company operates three integrated business segments: R&D Services for pharmaceutical companies, Clinical Diagnostics (leveraging Roche partnership for cobas e platform deployment), and Drug Development (DACRA molecules with Eli Lilly). Key differentiators include 30+ years of ECM research expertise, FDA Letters of Support for multiple biomarkers, and CAP accreditation in Scandinavia.
Differentiator
Problem solved
Functional benefit
Products and services
- Laboratory Services CAP/CLIA-accredited central laboratory services offering biomarker analysis, preclinical and clinical sample analysis, and drug development support for biotech and pharmaceutical industries. Services include central lab, specialty lab, and regulatory services with 24-hour turnaround on samples analyzed from clients globally.
- NordicPRO-C3 (PRO-C3) Neo-epitope biomarker assay quantifying a fragment of type III collagen released during extracellular matrix remodeling, enabling non-invasive measurement of active fibrogenesis and dynamic assessment of fibrosis progression and treatment response. Available via laboratory services or Kit in a Box manual ELISA for Research Use Only.
- NordicPRO-C6 (PRO-C6) Biomarker assay measuring a fragment of type VI collagen (Endotrophin signaling molecule), enabling non-invasive quantification of fibrogenesis, tissue remodeling, and wound healing across chronic diseases. FDA-supported for HFpEF trial enrichment. Runs on the Roche Cobas e automated platform.
- RheumaTrace Blood-based biomarker assay quantifying type I collagen turnover, serving as a pharmacodynamic marker for rheumatoid arthritis treatment monitoring and joint tissue remodeling assessment.
- CPa9-HNE (NordicCPa9-HNE) Biomarker assay measuring a fragment of S100A9 (calprotectin) released by neutrophil elastase in blood, enabling precise assessment of active neutrophil-driven inflammation in systemic and tissue-specific conditions. FDA Letter of Support received for IBD applications.
- FIB-NIT Biomarker Panel Fibrosis Non-Invasive Tests biomarker panel combining multiple extracellular matrix turnover markers for comprehensive non-invasive assessment of fibrotic diseases across organ systems.
- Kit in a Box Convenient, lab-ready manual ELISA kit products (including PRO-C3) for Research Use Only in non-clinical settings, enabling customers to run biomarker assays in their own laboratories.
- Endotrophin (nordicEndotrophin) Biomarker assay quantifying the intact 77-amino-acid Endotrophin signaling hormone (bioactive fragment of type VI collagen), enabling non-invasive quantification of fibro-inflammatory signaling and risk stratification in chronic disease and oncology.
- NordicIBDTrace Biomarker panel specifically designed for inflammatory bowel disease, measuring extracellular matrix turnover markers relevant to intestinal inflammation and fibrosis assessment.
- Translational Models Pre-clinical research services including in vitro 3D hydrogel cell cultures (via Ectica Technologies partnership) for fibrosis drug discovery, providing a translational in vitro platform for compound screening.
Quantifiable outcome
- 12.4% and 9.2% increase in cardiovascular or all-cause mortality risk per 1 ng/ml rise in PRO-C6
- +2 more outcomes
Companies that use Nordic Bioscience
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Nordic Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature7 records
Nordic Bioscience partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered flagship, core and regional.
- Roche DiagnosticsflagshipPRO-C3 biomarker officially launched by Roche Diagnostics on Cobas platform, making it available globally for research and diagnostic use in fibrosis and chronic diseases.
- Eli LillyflagshipKeyBioscience, a fully owned subsidiary and affiliate of Nordic Bioscience, announced extension of strategic collaboration with Eli Lilly for development of DACRA molecules for obesity and metabolic diseases treatment.
- GRIPonMASH ConsortiumcoreNordic Bioscience joined consortium of 27 European institutions to develop GRIPonMASH Diagnostic Platform for early detection of MASH, better patient stratification, and personalized lifestyle advice. Four-year project supported by IHI JU.
- LabCorp (China)regionalLicense agreement between Nordic Bioscience and Roche enables PRO-C3 availability as Research Use Only product in China via LabCorp Shanghai, providing broader market access for Chinese drug developers.
- University Medicine RostockcoreNordic Bioscience joined the CombiDiag consortium, a Marie Skłodowska-Curie doctoral network funded by European Commission, focused on early detection of Alzheimer's disease using AI and data-supported diagnostic protocols including blood-based biomarkers.
- Ectica TechnologiescoreStrategic alliance combining Nordic Bioscience's ECM biomarker expertise with Ectica's 3D hydrogel cell culture technology for translational in vitro drug discovery models in fibrosis. Ectica licenses its cell culture platform enabling Nordic to conduct pre-clinical drug discovery services.
- Bristol Myers SquibbflagshipCollaboration with Bristol Myers Squibb and University of Pennsylvania resulted in PRO-C6/Endotrophin publication in NEJM Evidence for HFpEF trial enrichment. FDA Letter of Support obtained for using PRO-C6 in clinical trial patient selection.
- Roche DiagnosticsflagshipStrengthened collaboration for development of biomarkers for chronic diseases. PRO-C3 and PRO-C6 biomarkers transferred to Roche Cobas platform for global distribution. License agreement enables biomarker availability in China via LabCorp.
- KeyBioscience (Subsidiary)coreFully owned subsidiary managing DACRA drug development collaboration with Eli Lilly for obesity and other metabolic indications.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Nordic Bioscience competitors and assessment
Company assessmentBroad incumbents
- Myriad Genetics: Established molecular diagnostics company commercializing proprietary biomarker tests (e.g., myChoice HRD, Vectra DA for RA disease activity). Comparable as a clinical-grade biomarker company serving pharma R&D and clinical decision-making, though with a much broader gene-expression and germline focus rather than ECM neo-epitopes.
- Eurofins Scientific: Global contract laboratory network offering biomarker, genomic, and bioanalytical services to pharma. Overlaps with Nordic on biomarker assay services and central lab work, though Eurofins is a far broader CRO-style operation across multiple industries.
- LabCorp (Laboratory Corporation of America): Large clinical diagnostics and central lab services company with extensive pharma R&D central lab operations. Comparable as a global biomarker lab services provider and channel partner (LabCorp Shanghai already distributes Nordic's PRO-C3 RUO in China).
- Covance (Labcorp Drug Development): Global CRO with deep central lab, bioanalytical, and biomarker services for clinical trials. Overlaps with Nordic on bioanalytical biomarker testing and central lab services, though at much larger scale across many therapeutic areas.
Direct peers
- Rules-Based Medicine (a Q² Solutions company): Provides multiplexed biomarker testing services for clinical trials and pharmaceutical R&D. Directly comparable to Nordic Bioscience's lab services arm, with overlapping customer base (large pharma sponsors) and similar focus on protein-based biomarker panels for drug development.
- SomaLogic: Protein biomarker discovery and diagnostics platform using aptamer-based proteomics (SomaScan). Direct competitor in protein-based biomarker services for pharma R&D and clinical applications, with comparable customer base among large pharma sponsors.
- Olink Holding: Provides proximity extension assay (PEA) technology for high-multiplex protein biomarker discovery and analysis. Directly comparable to Nordic ProteinFingerPrint on the protein biomarker platform dimension, serving pharma biomarker R&D with overlapping use cases including inflammation, oncology, and cardiometabolic disease.
- Celerion: Early-phase clinical and bioanalytical CRO providing biomarker and PK/PD services to pharma. Comparable service offering and customer base to Nordic's biomarker lab services, particularly for translational and pharmacodynamic biomarker work.
- Meso Scale Diagnostics: Manufacturer of multiplex immunoassay platforms (Meso Scale Discovery / MSD) widely used for protein biomarker validation in pharma R&D. Comparable as a protein biomarker technology provider serving pharma, though focused on instrument/platform sales rather than a proprietary neo-epitope biomarker franchise like Nordic.
Emerging players
- Biodesix: Protein-based diagnostics company focused on lung disease and oncology with blood-based tests. Comparable as a small/mid-cap biomarker commercializer with pharma R&D services, though smaller scale and narrower therapeutic focus than Nordic Bioscience.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Nordic Bioscience social profiles
Digital presenceNordic Bioscience compliance and trust
Trust signalCompliance3 records
Nordic Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nordic Bioscience leadership team
Management profileNumber of profiles
Profiles3 records
Nordic Bioscience subsidiaries and ownership
Company hierarchySubsidiaries1 record
Nordic Bioscience funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nordic Bioscience M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nordic Bioscience
What does Nordic Bioscience do?
Nordic Bioscience develops and commercializes proprietary neo-epitope biomarker assays targeting extracellular matrix (ECM) protein fragments for pharmaceutical and biotechnology drug development. Its core offerings are delivered through two channels: (1) CAP/CLIA-accredited central laboratory biomarker analysis services and (2) Kit in a Box manual ELISA products for Research Use Only. The company also licenses biomarkers to Roche Diagnostics for global IVD distribution on the Cobas platform and develops DACRA drug candidates through its KeyBioscience subsidiary.
Is Nordic Bioscience a public or private company?
Nordic Bioscience is a private company. It is classified as private equity controlled and is currently operating.
When was Nordic Bioscience founded?
Nordic Bioscience was founded in 1989. It employs 51 to 100 people.
Where is Nordic Bioscience based?
Nordic Bioscience is headquartered in Herlev, Denmark, in the Europe region.
How does Nordic Bioscience make money?
Four revenue lines are on record. R&D Services are the primary driver. The others are clinical Diagnostics, drug Development and biomarker Kits and Products.
Who are Nordic Bioscience's main competitors?
Broad incumbents on record are Myriad Genetics, Eurofins Scientific, LabCorp (Laboratory Corporation of America) and Covance (Labcorp Drug Development). Direct peers are Rules-Based Medicine (a Q² Solutions company), SomaLogic, Olink Holding, Celerion and Meso Scale Diagnostics. Biodesix is listed as an emerging player.
Does Nordic Bioscience have an API?
No public API is recorded for Nordic Bioscience.
What industry is Nordic Bioscience in?
Nordic Bioscience's product category is Biomarker Assay Development & Clinical Laboratory Services. Its primary akta.pro industry code is HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation), with a secondary code of HLAAAMAD, Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers). Its NAICS code is 541714 and its SIC code is 2835.